Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Amakem Therapeutics
Device/Diagnostics Quarterly Deal Statistics, Q2 2016
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
Deals In Depth: December 2015
Bristol-Myers Squibb sold its HIV pipeline to Viiv for $2.9 billion; AstraZeneca acquired a potential Imbruvica competitor by getting a controlling stake in Acerta; biopharma financing was up significantly thanks to a $7.2 billion ADS/debt offering by Teva Pharmaceutical.
Medical Device Deals Update, January 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced November-December 2015.
Deals Shaping The Medical Industry, January 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2015.
- Other Names / Subsidiaries
- Amakem NV
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.